Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Stay updated with breaking news from Life Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
By Ben Glickman Sellas Life Sciences Group said Wednesday its Phase 1 trial of its leading clinical candidate showed positive results. The New York-based...
The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Rating)’s stock price traded up 4.2% on Thursday . The company traded as high as $1.78 and last traded at $1.72. 248,797 shares changed hands during trading, a decline of 24% from the average session volume of 326,349 shares. The stock had previously closed at $1.65. Analyst […]
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Rating)’s stock price traded down 0.6% on Wednesday . The company traded as low as $1.66 and last traded at $1.72. 137,316 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 354,253 shares. The stock had previously closed at $1.73. […]